| NCT ID | NCT06067347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | T-Cell and NK-Cell Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2024-01-05 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2024-01-05 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
Eligibility Criteria
Inclusion Criteria: * Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm. * All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders. Exclusion Criteria: * Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders. * Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06067347 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying T-Cell and NK-Cell Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06067347 currently recruiting?
Yes, NCT06067347 is actively recruiting participants. Contact the research team at salvia.jain@mgh.harvard.edu for enrollment information.
Where is the NCT06067347 trial being conducted?
This trial is being conducted at Duarte, United States, Denver, United States, Tampa, United States, Boston, United States and 10 additional locations.
Who is sponsoring the NCT06067347 clinical trial?
NCT06067347 is sponsored by Massachusetts General Hospital. The trial plans to enroll 1,200 participants.